CoChat

Glucagon‐like peptide‐1 receptor expression on human eosinophils and its regulation of eosinophil activation

Mitchell, P. D., Salter, B. M., Oliveria, J. P., El‐Gammal, A., Tworek, D., Smith, S. G., Sehmi, R., Gauvreau, G. M., Butler, M., O'Byrne, P. M. · 2017 · Clinical & Experimental Allergy
Cited by 78

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Summary: Background: Glucagon‐like peptide‐1 (GLP‐1) and its receptor are part of the incretin family of hormones that regulate glucose metabolism. GLP‐1 also has immune modulatory roles. Objectives: To measure the expression of the GLP‐1 receptor (GLP‐1R) on eosinophils and neutrophils in normal and asthmatic subjects and evaluate effects of a GLP‐1 analog on eosinophil function. Methods: Peripheral blood samples were taken from 10 normal and 10 allergic asthmatic subjects. GLP‐1R expression was measured on eosinophils and neutrophils. Subsequently, the asthmatic subjects underwent allergen and diluent inhalation challenges, and GLP‐1R expression was measured. Purified eosinophils, collected from mild asthmatic subjects, were stimulated with lipopolysaccharide (LPS) and a GLP‐1 analog to evaluate eosinophil cell activation markers CD 11b and CD 69 and cytokine (IL‐4, IL‐5, IL‐8 and IL‐13) production. Results: Glucagon‐like peptide‐1 receptor is expressed on human eosinophils and neutrophils. Eosinophil, but not neutrophil, expression of GLP‐1R is significantly higher in normal controls compared to allergic asthmatics. The expression of GLP‐1R did not change on either eosinophils or neutrophils following allergen challenge. A GLP‐1 analog significantly decreased the expression of eosinophil‐surface activation markers following LPS stimulation and decreased eosinophil production of IL‐4, IL‐8 and IL‐13, but not IL‐5. Conclusion and Clinical Relevance: Glucagon‐like peptide‐1 receptor is expressed on human eosinophils and neutrophils. A GLP‐1 analog attenuates LPS‐stimulated eosinophil activation. GLP‐1 agonists may have additional adjunctive indications in treating persons with concomitant type 2 diabetes mellitus and asthma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cea.12860

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 78

Metadata

Authors
Mitchell, P. D., Salter, B. M., Oliveria, J. P., El‐Gammal, A., Tworek, D., Smith, S. G., Sehmi, R., Gauvreau, G. M., Butler, M., & O'Byrne, P. M.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2017-01-28
Volume
47
Issue
3
Pages
331-338
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W2560130766
Cited by
78
References
10
FWCI
2.51
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon‐like peptide‐1 receptor expression on human eosinophils and its regulation of eosinophil activation. https://app.cochat.ai/papers/10.1111/cea.12860
The paper
Mitchell, P. D., Salter, B. M., Oliveria, J. P., El‐Gammal, A., Tworek, D., Smith, S. G., Sehmi, R., Gauvreau, G. M., Butler, M., & O'Byrne, P. M. (2017). Glucagon‐like peptide‐1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.12860

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.